ACTR and BOXR: Addressing the Challenges of T-Cell Therapies in Solid Tumors

Time: 4:55 pm
day: Day Two


  • Key challenges facing T-cell therapy in solid tumors include on-target/off tumor toxicity and immunosuppression in the tumor microenvironment. Unum has developed two novel T cell technologies to address these challenges
  • The ACTR T-cell platform allows for selective tumor antigen targeting efficiently killing tumor cells with high antigen expression while sparing normal tissues with low antigen expression
  • The BOXR T-cell platform enables engineered T-cells to overcome specific mechanisms of TME immunosuppression that include metabolic competition immunosuppressive cell types (Treg, MDSC), and exhaustion due to chronic stimulation